Zydus reports positive Phase II(b) EVIDENCES-X results for Saroglitazar Mg in MASH
Global trial met its primary endpoint of MASH resolution without worsening of fibrosis at week 52
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Saroglitazar Mg
Lupin, Zydus sign licensing pact to co-market Saroglitazar Mg for chronic liver diseases in India
In 2020, Saroglitazar Mg received approval for the treatment of NASH and NAFLD
Zydus announces Phase IV EVIDENCES-XI trial to generate RWE of Saroglitazar Mg in NAFLD patients…
Phase IV EVIDENCES- XI trial will enroll approximately 1500 NAFLD patients with comorbidities
Zydus announces EPICS-IIITM phase-II(b)/III adaptive pivotal clinical trial of Saroglitazar Mg in…
Positive results from the phase-II(a) clinical trial evaluating Saroglitazar Mg in patients with NASH were published in the…
EMA grants Orphan Drug Designation to Saroglitazar Mg for treating patients with PBC
The Orphan drug status in Europe is given to medicines with the potential to be safe and effective treatments for rare,…
US FDA grants Orphan Drug Designation to Zydus’ Saroglitazar for primary biliary cholangitis…
This follows the grant of ‘Fast Track Designation’ by the USFDA to Saroglitazar Mg for PBC in December 2020
Zydus gets DCGI approval for Saroglitazar Mg to treat non-alcoholic fatty liver disease
Saroglitazar Mg is already approved for the treatment of type-2 diabetes and NASH